Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 18:56:35·⟳ 抓取 18:56:58 +23s·⚡ 决策 10-27 20:27:59 +1h31m·5.9 小时前
Vanda（VNDA）NEREUS预防GLP-1相关呕吐III期Study 3601达主要终点，拟提交sNDA
本条为Investing.com对Vanda当日06:50 ET PR Newswire一手通稿的AI生成转述，数据点与已处理记录完全一致，无新增金额、监管阶段或官方更新；该催化已由wire源在本臂给出VNDA.US ENTER决策，再开新仓属于同一事件重复下注。
📄 原文Investing.com↗ 原文
Vanda reports positive trial results for GLP-1 vomiting drug
WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced today that its Phase III trial of NEREUS (tradipitant)…
不做 Vanda Pharmaceuticals Inc.（VNDA.US）
重复事件去重：Study 3601阳性催化已由PR Newswire一手通稿源在本臂研判并给出VNDA.US ENTER（盘前约+7%），本条Investing.com为AI生成二手转述、无新增事实，再开仓将重复计入同一敞口；以既有ENTER腿为准，不在此叠加。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
NEREUS III期阳性、拟报sNDA确为直接利好，但同一Study 3601催化已在1.5小时内由一手通稿源研判并出手；本条二手转述无任何增量事实，故不重复开仓。
消息传播链
- 公司首发Study 3601 III期阳性结果及sNDA计划，为本事件一手来源
- AI生成、编辑审核的二手转述，数据与一手通稿一致，无新增事实
关键理由
- 事件本身正面：主要终点p=0.006、极端呕吐降低81%，且为已上市药物的适应症扩展（sNDA而非全新BLA），监管与安全性风险相对低
主要风险
- sNDA提交窗口约在2027年，短期无收入兑现，小盘临床读出波动大；该风险已在既有ENTER腿中承接
先例如何影响了这次决策
对本次决策的影响:不改变既有ENTER腿；本条仅输出去重AVOID
方向:未独立检索：本条在跨源查重阶段即确认为同一催化的重复转述，既有wire源决策已先行，不再重复以先例校准
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{ - search_processed_events 成功 stock_tools HTTP · 428 ms
{"result": "search_processed_events:agent query=`vanda pharmaceuticals nereus tradipitant phase iii glp-1 vomiting | vnda study 3601 semaglutide nk-1 antagonist positive results`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 70.2/72 小时、5108 条本臂决策(完整)，返回 1 条候选。\n• 10-27 12:26 UTC(北京 20:26) [bm25:65%] 值得做 VNDA.US (wire) — - stock_quote 成功 stock_tools HTTP · 560 ms
{ - web_search 成功 doubao_search · 8,235 ms
豆包搜索结果（原始查询:Vanda Pharmaceuticals NEREUS tradipitant Phase 3 GLP-1 vomiting results press release；API SearchType:web）
原文全文
展开原文 · 1,900 字
WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced today that its Phase III trial of NEREUS (tradipitant) met its primary endpoint for preventing vomiting in patients receiving GLP-1 receptor agonist therapy, according to a press release statement.
The randomized, placebo-controlled Study 3601 enrolled 306 participants who received a single 1 mg dose of semaglutide. Vomiting occurred in 43.0% of NEREUS-treated participants (61/142) compared with 58.5% on placebo (96/164), representing a 27% relative reduction (p=0.006).
The key secondary endpoint of vomiting combined with severe nausea occurred in 33.1% of NEREUS participants versus 50.6% on placebo (p=0.002), a 35% relative reduction.
Exploratory analyses showed frequent multi-day vomiting (more than two episodes on more than one day) occurred in 6.3% of NEREUS participants versus 15.9% on placebo (p=0.008), a 60% relative reduction. Extreme vomiting (greater than 10 total episodes) occurred in 2.8% versus 14.6% on placebo (p=0.0003), an 81% relative reduction.
The study used a single 1 mg semaglutide dose without gradual titration to create conditions producing high vomiting rates. Most vomiting episodes occurred by Day 2 in both groups.
NEREUS is an oral NK-1 receptor antagonist that received FDA approval in December 2025 for prevention of motion-induced vomiting. The company stated it plans to discuss results with the FDA and intends to submit a supplemental New Drug Application for the GLP-1-related vomiting indication.
Vanda stated the drug was generally well tolerated with no new safety signals observed.
The company cited studies indicating approximately half of patients discontinue GLP-1 therapy within one year, with gastrointestinal side effects among leading reasons for discontinuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The randomized, placebo-controlled Study 3601 enrolled 306 participants who received a single 1 mg dose of semaglutide. Vomiting occurred in 43.0% of NEREUS-treated participants (61/142) compared with 58.5% on placebo (96/164), representing a 27% relative reduction (p=0.006).
The key secondary endpoint of vomiting combined with severe nausea occurred in 33.1% of NEREUS participants versus 50.6% on placebo (p=0.002), a 35% relative reduction.
Exploratory analyses showed frequent multi-day vomiting (more than two episodes on more than one day) occurred in 6.3% of NEREUS participants versus 15.9% on placebo (p=0.008), a 60% relative reduction. Extreme vomiting (greater than 10 total episodes) occurred in 2.8% versus 14.6% on placebo (p=0.0003), an 81% relative reduction.
The study used a single 1 mg semaglutide dose without gradual titration to create conditions producing high vomiting rates. Most vomiting episodes occurred by Day 2 in both groups.
NEREUS is an oral NK-1 receptor antagonist that received FDA approval in December 2025 for prevention of motion-induced vomiting. The company stated it plans to discuss results with the FDA and intends to submit a supplemental New Drug Application for the GLP-1-related vomiting indication.
Vanda stated the drug was generally well tolerated with no new safety signals observed.
The company cited studies indicating approximately half of patients discontinue GLP-1 therapy within one year, with gastrointestinal side effects among leading reasons for discontinuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ee2aa0f214· 2026-10-27 20:27 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前